This Article Full Text (PDF) All Versions of this Article: 0269881106065907v1 20/6/842    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (8) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Yang, J. Articles by Rostami-Hodjegan, A. Search for Related Content PubMed PubMed Citation Articles by Yang, J. Articles by Rostami-Hodjegan, A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB 3,4-METHYLENEDIOXYMETHAMPHETAMINE Medline Plus Health Information Club Drugs Social Bookmarking                   What's this?

Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA

Masoud Jamei

Amir Heydari

Karen R. Yeo

Simcyp Limited, Sheffield, UK

Rafael de la Torre

Magí Farré

Institut Municipal d'Investigació Mèdica, Barcelona, Spain

Geoffrey T. Tucker

Amin Rostami-Hodjegan

University of Sheffield, Sheffield, UK

The aim of this study was to model the in vivo kinetic consequences of mechanism-based inhibition (MBI) of CYP2D6 by 3,4 methylenedioxymethamphetamine (MDMA, ecstasy). A model with physiologically-based components of drug metabolism was developed, taking account of change in the hepatic content of active CYP2D6 due to MBI by MDMA. Based on the in vitro information, plasma concentration time profiles of MDMA after various doses were computed and compared with reported observations. The analysis suggested that a typical recreational MDMA dose could inactivate most hepatic CYP2D6 within an hour, and the return to a basal level of CYP2D6 could take at least 10 days. Thus, the genetic polymorphism of CYP2D6 and coadministration of CYP2D6 inhibitors may have less impact on MDMA pharmacokinetics and the risk of acute toxicity than previously thought. This is consistent with clinical observations that indicate no obvious link between inherited CYP2D6 deficiency and acute MDMA intoxication.

Key Words: ecstasy • inactivation • MDMA • mechanism-based inhibition • modelling

This version was published on November 1, 2006

Journal of Psychopharmacology, Vol. 20, No. 6, 842-849 (2006)
DOI: 10.1177/0269881106065907


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				X. Perfetti, B. O'Mathuna, N. Pizarro, E. Cuyas, O. Khymenets, B. Almeida, M. Pellegrini, S. Pichini, S. S. Lau, T. J. Monks, et al. Neurotoxic Thioether Adducts of 3,4-Methylenedioxymethamphetamine Identified in Human Urine After Ecstasy Ingestion Drug Metab. Dispos., July 1, 2009; 37(7): 1448 - 1455. [Abstract] [Full Text] [PDF]

				S. W. Grimm, H. J. Einolf, S. D. Hall, K. He, H.-K. Lim, K.-H. J. Ling, C. Lu, A. A. Nomeir, E. Seibert, K. W. Skordos, et al. The Conduct of in Vitro Studies to Address Time-Dependent Inhibition of Drug-Metabolizing Enzymes: A Perspective of the Pharmaceutical Research and Manufacturers of America Drug Metab. Dispos., July 1, 2009; 37(7): 1355 - 1370. [Abstract] [Full Text] [PDF]

				M. Mueller, F. T. Peters, H. H. Maurer, U. D. McCann, and G. A. Ricaurte Nonlinear Pharmacokinetics of ({+/-})3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") and Its Major Metabolites in Squirrel Monkeys at Plasma Concentrations of MDMA That Develop After Typical Psychoactive Doses J. Pharmacol. Exp. Ther., October 1, 2008; 327(1): 38 - 44. [Abstract] [Full Text] [PDF]